The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Takeda H, Nishikawa H, Iguchi E, Matsuda F, Kita R, Kimura T, Osaki Y

Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases.

Clinical journal of gastroenterology 2012;5;407-12 — 2012 — 407-12

Horiuchi-Yamamoto Y, Gemma A, Taniguchi H, Inoue Y, Sakai F, Johkoh T, Fujimoto K, Kudoh S

Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.

International journal of clinical oncology 2013 Aug;18;743-9 — 2013 Aug — 743-9

Myung HJ, Jeong SH, Kim JW, Kim HS, Jang JH, Yoon HI, Kim JS

Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report.

Gut and liver 2010 Dec;4;543-6 — 2010 Dec — 543-6

Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Jan 01;29;69-75 — 2011 Jan 01 — 69-75